MCID: ANL011
MIFTS: 39

Anal Canal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Anal Canal Carcinoma

MalaCards integrated aliases for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 57 12 13 44 15
Carcinoma of Anal Canal 12 73
Anal Canal Cancer 12 15
Anal Canal and Perianal Gland Carcinoma 12
Cancer of the Anal Canal 37

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
anal canal carcinoma:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 105580
Disease Ontology 12 DOID:0050688 DOID:6126
MeSH 44 C563020
NCIt 50 C7489
MedGen 42 C0563211
KEGG 37 H00044
ICD10 33 C21.1
SNOMED-CT via HPO 69 263681008
UMLS 73 C0563211

Summaries for Anal Canal Carcinoma

Disease Ontology : 12 An anal canal cancer that derives from epithelial cells.

MalaCards based summary : Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to small cell carcinoma and transitional cell carcinoma. An important gene associated with Anal Canal Carcinoma is ANC (Anal Canal Carcinoma), and among its related pathways/superpathways is Viral carcinogenesis. The drugs Fluorouracil and Nivolumab have been mentioned in the context of this disorder. Affiliated tissues include prostate, skin and lung, and related phenotype is anal canal squamous carcinoma.

Description from OMIM: 105580

Related Diseases for Anal Canal Carcinoma

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Related Disease Score Top Affiliating Genes
1 small cell carcinoma 29.8 KRT7 CDKN2A
2 transitional cell carcinoma 29.7 KRT7 CDKN2A
3 anal carcinoma in situ 11.4
4 anal canal adenocarcinoma 11.2
5 anal canal squamous cell carcinoma 11.2
6 hypopharynx cancer 10.1 NME1 CD6
7 pharynx cancer 10.1 CDKN2A CD6
8 cervical intraepithelial neoplasia 10.1 NME1 CDKN2A
9 skin melanoma 10.1 NME1 CDKN2A
10 tongue disease 10.1 CDKN2A CD6
11 laryngeal squamous cell carcinoma 10.1 NME1 CDKN2A
12 rectal disease 10.1 CDKN2A CD6
13 nasopharyngeal disease 10.0 CDKN2A CD6
14 larynx cancer 10.0 NME1 CDKN2A
15 inverted transitional papilloma 10.0 KRT7 CDKN2A
16 papilloma 10.0 KRT7 CDKN2A
17 bladder carcinoma in situ 10.0 KRT7 CDKN2A
18 endocervical carcinoma 10.0 KRT7 CDKN2A
19 bile duct adenoma 10.0 KRT7 CDKN2A
20 adenoid basal cell carcinoma 10.0 KRT7 CDKN2A
21 vulval paget's disease 10.0 KRT7 CDKN2A
22 nasal cavity cancer 10.0 KRT7 CDKN2A
23 nasal cavity adenocarcinoma 10.0 KRT7 CDKN2A
24 vulvar disease 10.0 KRT7 CDKN2A
25 vulva adenocarcinoma 10.0 KRT7 CDKN2A
26 glycogen-rich clear cell breast carcinoma 10.0 KRT7 CDKN2A
27 well-differentiated liposarcoma 10.0 KRT7 CDKN2A
28 mucinous bronchioloalveolar adenocarcinoma 10.0 KRT7 CDKN2A
29 endocervical adenocarcinoma 10.0 CDKN2A KRT7
30 cervical adenocarcinoma 10.0 KRT7 CDKN2A
31 nasal cavity squamous cell carcinoma 10.0 CDKN2A KRT7
32 necrotizing sialometaplasia 10.0 CDKN2A KRT7
33 basaloid squamous cell carcinoma 10.0 CDKN2A KRT7
34 cervical adenosquamous carcinoma 10.0 KRT7 CDKN2A
35 adenocarcinoma in situ 10.0 KRT7 CDKN2A
36 biliary tract neoplasm 9.9 KRT7 CDKN2A
37 prostate cancer 9.9
38 basal cell carcinoma 1 9.9
39 basal cell carcinoma 9.9
40 horner's syndrome 9.9 KRT7 CD6
41 tonsil cancer 9.9 KRT7 CDKN2A
42 squamous cell carcinoma 9.9
43 mammary paget's disease 9.9
44 suppression of tumorigenicity 12 9.9
45 leukemia 9.9
46 adenocarcinoma 9.9
47 laryngeal disease 9.9 NME1 CDKN2A CD6
48 vulva cancer 9.9 KRT7 CDKN2A
49 mucinous adenocarcinoma 9.9 KRT7 CDKN2A
50 pancreatic ductal carcinoma 9.9 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to Anal Canal Carcinoma

Symptoms & Phenotypes for Anal Canal Carcinoma

Symptoms via clinical synopsis from OMIM:

57
Oncology:
anal canal squamous carcinoma


Clinical features from OMIM:

105580

Human phenotypes related to Anal Canal Carcinoma:

32
# Description HPO Frequency HPO Source Accession
1 anal canal squamous carcinoma 32 HP:0006763

Drugs & Therapeutics for Anal Canal Carcinoma

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 2 51-21-8 3385
2
Nivolumab Approved Phase 2,Phase 1 946414-94-4
3
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
4
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
5
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
6
Daratumumab Approved Phase 1, Phase 2 945721-28-8
7
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9 Mitoguazone Investigational Phase 2 459-86-9
10 Anti-Bacterial Agents Phase 2
11 Nucleic Acid Synthesis Inhibitors Phase 2
12 Mitomycins Phase 2
13 Alkylating Agents Phase 2
14 Antibiotics, Antitubercular Phase 2
15 Antibodies Phase 2,Phase 1
16 Immunoglobulins Phase 2,Phase 1
17 Immunologic Factors Phase 2,Phase 1
18 Antibodies, Monoclonal Phase 2,Phase 1
19 Immunosuppressive Agents Phase 2
20 Antimetabolites Phase 2
21 Antimetabolites, Antineoplastic Phase 2
22 taxane Phase 2
23 Antimitotic Agents Phase 2
24 Liver Extracts Phase 2
25 Antineoplastic Agents, Phytogenic Phase 2
26 Albumin-Bound Paclitaxel Phase 2
27 Vaccines Phase 2

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
2 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
3 Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Recruiting NCT02314169 Phase 2
4 Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers Terminated NCT01382745 Phase 2 Nimotuzumab
5 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
6 Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
7 Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal Terminated NCT01843452 Phase 2 MITOMYCIN;CAPECITABINE
8 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy Recruiting NCT03597295 Phase 2 INCMGA00012
9 Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Recruiting NCT02437851 Phase 2
10 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
11 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
12 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
13 Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
14 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Recruiting NCT03233711 Phase 2
15 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
16 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
17 Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates Completed NCT03465501
18 Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers Active, not recruiting NCT01325961 Not Applicable
19 "Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection Not yet recruiting NCT03731754 Not Applicable
20 Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal Recruiting NCT01845779 Not Applicable DCF regimen
21 Individual Following in Anal Cancer With PET/CT Recruiting NCT02697084
22 Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer Completed NCT00325871

Search NIH Clinical Center for Anal Canal Carcinoma

Cochrane evidence based reviews: anal canal carcinoma

Genetic Tests for Anal Canal Carcinoma

Anatomical Context for Anal Canal Carcinoma

MalaCards organs/tissues related to Anal Canal Carcinoma:

41
Prostate, Skin, Lung, Tongue, Breast, Tonsil, Bone Marrow

Publications for Anal Canal Carcinoma

Articles related to Anal Canal Carcinoma:

(show top 50) (show all 84)
# Title Authors Year
1
Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. ( 29891206 )
2018
2
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. ( 30128811 )
2018
3
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). ( 30172453 )
2018
4
Synchronous anal canal carcinoma in a heterosexual couple. ( 30200930 )
2018
5
Anal Canal Carcinoma in a Child With Disorders of Sex Development. ( 27037640 )
2016
6
Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal carcinoma. ( 27976366 )
2016
7
Urethral dose sparing in squamous cell carcinoma of anal canal using proton therapy matching electrons with prior brachytherapy for prostate cancer: A case study. ( 27396941 )
2016
8
The impact of anaemia on treatment outcome in patients with squamous cell carcinoma of anal canal and anal margin. ( 27069457 )
2016
9
Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. ( 27004217 )
2016
10
Shifting paradigm in the management of anal canal carcinoma. ( 25432583 )
2015
11
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. ( 25903798 )
2015
12
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? ( 25976929 )
2015
13
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243447 )
2014
14
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. ( 24472223 )
2014
15
Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 24243421 )
2014
16
Rhabdoid carcinoma of anal canal: role of electron microscopy and immunohistochemistry in establishing lineage. ( 25192454 )
2014
17
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. ( 23674135 )
2013
18
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. ( 24674573 )
2013
19
Changing patterns of anal canal carcinoma in the United States. ( 23509304 )
2013
20
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. ( 21395883 )
2012
21
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. ( 22529257 )
2012
22
Chemotherapy in the treatment of anal canal carcinoma. ( 22658644 )
2012
23
Endobronchial metastases of anal canal carcinoma. ( 22055765 )
2012
24
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. ( 20472349 )
2011
25
Anal canal carcinoma treatment results: the experience of a single institution. ( 21403412 )
2011
26
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. ( 21772841 )
2011
27
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. ( 22331724 )
2011
28
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. ( 21775274 )
2011
29
A Phase I/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical Stage II/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC). ( 21467080 )
2011
30
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. ( 20492729 )
2010
31
Post burn Marjolin's ulcer in the natal cleft mimicking anal canal carcinoma: a rare site. ( 21160444 )
2010
32
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. ( 19399614 )
2010
33
Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. ( 20452695 )
2010
34
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. ( 19695047 )
2009
35
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). ( 18490648 )
2008
36
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. ( 18505075 )
2008
37
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). ( 18191265 )
2008
38
Chemotherapy and radiotherapy for anal canal carcinoma. ( 18812528 )
2008
39
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. ( 18005443 )
2007
40
External beam radiotherapy plus brachytherapy boost in treatment of anal canal carcinoma. ( 17988027 )
2007
41
Anal canal carcinoma: experience from a single Korean institution. ( 17963341 )
2007
42
Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. ( 17352019 )
2007
43
Anal canal carcinoma with Pagetoid spread: report of a case. ( 16794808 )
2006
44
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. ( 16631268 )
2006
45
T1 neuroendocrine carcinoma of anal canal after transanal resection for intramucosal adenocarcinoma. ( 16702164 )
2006
46
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. ( 15752894 )
2005
47
Epidermal growth factor receptor expression in anal canal carcinoma. ( 15923158 )
2005
48
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. ( 15890590 )
2005
49
Organ-preserving multimodality management of squamous cell carcinoma of anal canal. ( 16361764 )
2005
50
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. ( 12788191 )
2003

Variations for Anal Canal Carcinoma

Expression for Anal Canal Carcinoma

Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for Anal Canal Carcinoma

Pathways related to Anal Canal Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

GO Terms for Anal Canal Carcinoma

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.13 CDKN2A NME1 TENM1
2 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 8.62 CD6 TENM1

Molecular functions related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion molecule binding GO:0050839 8.62 SLC14A2 TENM1

Sources for Anal Canal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....